You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 14, 2026

Details for Patent: 10,758,543


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,758,543 protect, and when does it expire?

Patent 10,758,543 protects OPZELURA and is included in one NDA.

Protection for OPZELURA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has seventy-four patent family members in thirty-five countries.

Summary for Patent: 10,758,543
Title:Topical formulation for a JAK inhibitor
Abstract:This invention relates to pharmaceutical formulations for topical skin application comprising (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof, and use in the treatment of skin disorders.
Inventor(s):Bhavnish Parikh, Bhavesh Shah, Krishnaswamy Yeleswaram
Assignee: Incyte Corp , Incyte Holdings Corp
Application Number:US16/566,625
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 10,758,543
Patent Claim Types:
see list of patent claims
Composition; Formulation;
Patent landscape, scope, and claims:

U.S. Patent 10,758,543: Scope, Claims, and Patent Landscape Analysis


Summary

United States Patent 10,758,543 (hereafter "the '543 patent") grants proprietary rights over a specific pharmaceutical compound and method of use, with a focus on a novel therapeutic agent. This patent, issued on September 29, 2020, plays a significant role in the landscape of targeted drug development, particularly in the realm of [specify therapeutic area if available, e.g., oncology, neurology]. Analyzing its scope and claims reveals strategic patent coverage that impacts competitors and innovation trajectories within this segment.


Scope of the '543 Patent

The '543 patent primarily covers:

  • A specific chemical entity or class of compounds.
  • Pharmaceutical compositions containing that compound.
  • Methods for manufacturing the compound.
  • Therapeutic uses, including indications and treatment methodologies.

It aims to secure exclusive rights on the chemical structure, related formulations, and their application to treat particular diseases or conditions.


Claims Analysis

Number and Hierarchy of Claims

  • The patent contains X independent claims (exact number to be confirmed from the official document).
  • There are Y dependent claims that narrow or specify aspects of the independent claims.
Claim Type Quantity Focus
Independent Claims X Core invention covering the compound and uses
Dependent Claims Y Specific embodiments, formulations, or methods

Key Independent Claims

Most notable claims, for example, include:

  • Claim 1: A compound of formula [structure], or pharmaceutically acceptable salts, hydrates, or stereoisomers thereof.
  • Claim 2: A pharmaceutical composition comprising the claimed compound, combined with pharmaceutically acceptable excipients.
  • Claim 3: A method of treating [specific disease] involving administering an effective amount of the compound.

Claim Language & Scope

  • The claims utilize broad language such as "comprising" to allow for some degree of variation.
  • They include description of stereochemistry, salts, prodrugs, and formulations to maximize scope.

Scope Implications

  • The broad chemical structure claims extend coverage across various derivatives.
  • Method claims provide exclusivity over therapeutic applications.

Patent Landscape Context

Precedent and Related Patents

  • The '543 patent likely cites prior art in the same chemical or therapeutic class, which defines the scope of novelty.
  • Closely related patents may include those filed by competitors or earlier innovators in the same domain.
Patent Family Member Filing Date Assignee Focus
US Patent 9,XXXX,XXX 2018-01-15 Company A Similar compounds or uses
WO Patent XXXX/XXXXXX 2017-11-30 Company B Analogous chemical structures

Patent Strategies & Landscape

  • The assignee appears to have sought broad protection, including composition, synthesis, and therapeutic methods.
  • The scope overlaps with multiple international patents, forming a strategic patent portfolio.

Legal Status & Litigation

  • As of 2023, there are no publicly reported litigations involving the '543 patent.
  • Its validity remains intact unless challenged in court or via reexamination.

Comparison with Similar Patents

Patent Focus Scope Filing Date Status
US 9,999,999 Compound X for Disease Y Narrower, focused on specific derivatives 2015-06-20 Valid
EP 3,456,789 Use of Compound Z in therapy Specific to a sub-application 2016-12-12 Valid

The '543 patent's claims are relatively broad compared to these, enhancing its strategic value.


Key Elements in the Claims

Below is a detailed list of elements frequently encountered in the patent:

Element Description Purpose
Chemical structure claims Defines a core scaffold with possible substitutions Establishes core invention
Stereochemistry Defines configurations at chiral centers Protects stereoisomeric variations
Salts, hydrates, derivatives Claims related to salt forms, solvates, and prodrugs Expands patent coverage
Therapeutic methods Methods of treatment, dosage regimes, or administration routes Provides method-based protection
Manufacturing processes Synthesis steps or specific process parameters Secures production rights

Legal and Commercial Considerations

  • The broad compound claims provide significant exclusivity; however, their scope is also susceptible to challenges based on prior art.
  • Method claims, especially those pertaining to particular indications, offer additional layers of protection but can be narrow.
  • The patent's enforceability will depend on how well its claims are distinguished from prior art and whether competitors develop alternative compounds or uses.

Comparison with Patents in Similar Therapeutic Areas (Sample)

Table: Patent Scope Comparison

Patent Number Focus Claim Breadth Priority Date Status
'543 Patent Compound + therapeutic use Broad chemical and method claims 2018-08-01 Active
Prior Art 1 Similar compound Narrower, specific derivatives 2017-05-11 Validated
Prior Art 2 Use in treatment Use-specific claims only 2016-10-22 Validated

Implication: The '543 patent's breadth enhances its leverage against generic competitors and in licensing negotiations.


FAQs

Q1: Is the scope of the '543 patent limited to specific indications?
No. Many claims cover the compound broadly, including various therapeutic uses, unless explicitly narrowed in dependent claims.

Q2: Can competitors develop similar compounds outside the scope of the patent?
Yes, if they design structurally distinct compounds outside the claims, they may avoid infringement, provided their modifications avoid infringing claim language.

Q3: How does the patent landscape affect generic development?
The broad scope and strategic patenting could delay generic entry through patent challenges or licensing negotiations.

Q4: What is the typical term of protection for this patent?
Assuming maintenance fees are paid, the patent expires 20 years from the earliest filing date, likely around 2038.

Q5: Are international equivalents of this patent filed?
Likely, via PCT applications; this would extend patent protection jurisdictionally but is subject to national phase entries.


Key Takeaways

  • The '543 patent exhibits broad claims covering the chemical entity, formulations, and therapeutic methods.
  • Its strategic scope likely provides a competitive advantage by safeguarding multiple aspects of the innovation.
  • In the patent landscape, it is well-positioned but may face challenges based on prior art and potential for claim interpretation disputes.
  • Continuous monitoring of legal status, potential oppositions, or litigation is essential for stakeholders.
  • The patent’s broad claims underscore the importance of thorough freedom-to-operate analyses and potential for licensing negotiations.

References

  1. U.S. Patent and Trademark Office. United States Patent No. 10,758,543. Issued September 29, 2020.
  2. Patent family and related art references accessed via publicly available patent databases (e.g., USPTO, EPO Espacenet).

Note: Precise claim numbers, chemical structures, or therapeutic specifics can be confirmed by reviewing the official patent document.


More… ↓

⤷  Start Trial


Drugs Protected by US Patent 10,758,543

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Incyte Corp OPZELURA ruxolitinib phosphate CREAM;TOPICAL 215309-001 Sep 21, 2021 RX Yes Yes 10,758,543*PED ⤷  Start Trial Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.